Abstract
Introduction:
This study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms.
Methods:
Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots.
Results:
On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared > 50% of the variance across blood fractions (serum amyloid A R2 = 0.99, interleukin (IL)10 R2 = 0.95, fatty acid-binding protein (FABP) R2 = 0.94, I309 R2 = 0.94, IL-5 R2 = 0.94, IL-6 R2 = 0.94, eotaxin3 R2 = 0.91, IL-18 R2 = 0.87, soluble tumor necrosis factor receptor 1 R2 = 0.85, and pancreatic polypeptide R2 = 0.81). When examining protein concentrations across platforms, only five markers shared > 50% of the variance (beta 2 microglobulin R2 = 0.92, IL-18 R2 = 0.80, factor VII R2 = 0.78, CRP R2 = 0.74, and FABP R2 = 0.70).
Discussion:
The current findings highlight the importance of considering blood fractions and assay platforms when searching for AD relevant biomarkers.
Keywords
Alzheimer's disease, Biomarker discovery, Blood, Diagnostics, Meso Scale Discovery, Multiplex assay platform, Plasma, Preanalytic processing, Proteins, Rules Based Medicine, Serum, Standardization
Document Type
Journal Article
Date of Publication
2016
Faculty
Faculty of Health, Engineering and Science
Publisher
Elsevier
School
School of Medical Sciences
RAS ID
21902
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Comments
O'Bryant, S. E., Lista, S., Rissman, R. A., Edwards, M., Zhang, F., Hall, J., ... & Martins, R. (2016). Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 3(1), 27-34.
https://doi.org/10.1016/j.dadm.2015.12.003